Everything you ever wanted to know about cancer stem cells in neuroendocrine neoplasms but were afraid to ask
in Endocrine OncologySearch for other papers by Ignacio Ruz Caracuel in
Current site
Google Scholar
PubMed
Search for other papers by Sergio Pedraza-Arevalo in
Current site
Google Scholar
PubMed
Search for other papers by Teressa Alonso-Gordoa in
Current site
Google Scholar
PubMed
Search for other papers by Javier Molina-Cerrillo in
Current site
Google Scholar
PubMed
Search for other papers by Julie Earl in
Current site
Google Scholar
PubMed
Search for other papers by Bruno Sainz in
Current site
Google Scholar
PubMed
While the role of cancer stem cells (CSCs) in tumorigenesis, chemoresistance, metastasis and relapse has been extensively studied in solid tumors, such as adenocarcinomas or sarcomas, the same cannot be said for neuroendocrine neoplasms (NENs). While lagging, CSCs have been described in numerous NENs including gastrointestinal and pancreatic neuroendocrine neoplasms (PanNENs), and they have been found to play critical roles in tumor initiation, progression, and treatment resistance. However, it seems there is still skepticism regarding the role of CSCs in NENs, even in light of studies that support the CSC model in these tumors and the therapeutic benefit of targeting them. For example, in lung neuroendocrine carcinoids, a high percentage of CSCs have been found in atypical carcinoids, suggesting the presence of CSCs in these cancers. In PanNENs, CSCs marked by aldehyde dehydrogenases or CD90 have been identified, and targeting CSCs with inhibitors of molecular pathways has shown therapeutic potential. Overall, while evidence exists for the presence of CSCs in NENs, either the CSC field has neglected NENs or the NEN field has not fully embraced the CSC model. Both might apply and/or may be a consequence of the fact that NENs are a relatively rare and heterogeneous tumor entity, with confusing histology and nomenclature to match. Regardless, this review intends to summarize our current knowledge of CSCs in NENs and highlight the importance of understanding the role of CSCs in the biology of these rare tumors, with a special focus on developing targeted therapies to improve patients' outcomes.
Endocrine Oncology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
As an open-access journal, Endocrine Oncology articles are immediately available to read on publication, without restriction. The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Feb 2021 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 149 | 149 | 100 |
| PDF Downloads | 91 | 91 | 47 |
Online ISSN: 2634-4793
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519